Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $10,094 | $9,420 | $10,155 | $10,449 |
| % Growth | 7.2% | -7.2% | -2.8% | – |
| Cost of Goods Sold | $5,203 | $4,920 | $5,476 | $5,426 |
| Gross Profit | $4,891 | $4,500 | $4,679 | $5,023 |
| % Margin | 48.5% | 47.8% | 46.1% | 48.1% |
| R&D Expenses | $979 | $737 | $996 | $786 |
| G&A Expenses | -$476 | $973 | $1,139 | $2,629 |
| SG&A Expenses | -$56 | $3,099 | -$3,264 | $6,596 |
| Sales & Mktg Exp. | $421 | $2,126 | $2,088 | $3,967 |
| Other Operating Expenses | $2,565 | -$695 | $5,809 | -$3,538 |
| Operating Expenses | $3,489 | $3,141 | $3,542 | $3,845 |
| Operating Income | $1,402 | $1,359 | $1,138 | $1,178 |
| % Margin | 13.9% | 14.4% | 11.2% | 11.3% |
| Other Income/Exp. Net | -$31 | -$11 | -$40 | -$38 |
| Pre-Tax Income | $1,371 | $1,348 | $1,098 | $1,140 |
| Tax Expense | $212 | $406 | $104 | $172 |
| Net Income | $937 | $765 | $759 | $786 |
| % Margin | 9.3% | 8.1% | 7.5% | 7.5% |
| EPS | 0.35 | 0.29 | 0.29 | 0.3 |
| % Growth | 20.7% | 0% | -3.3% | – |
| EPS Diluted | 0.35 | 0.29 | 0.29 | 0.3 |
| Weighted Avg Shares Out | 2,663 | 2,663 | 2,663 | 2,663 |
| Weighted Avg Shares Out Dil | 2,663 | 2,663 | 2,663 | 2,663 |
| Supplemental Information | – | – | – | – |
| Interest Income | $87 | $76 | $93 | $91 |
| Interest Expense | $323 | $330 | $364 | $358 |
| Depreciation & Amortization | $0 | $0 | $0 | $320 |
| EBITDA | $1,694 | $1,677 | $1,462 | $1,819 |
| % Margin | 16.8% | 17.8% | 14.4% | 17.4% |